In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dunoyer Makes Leap To CFO As AZ’s BD Overhaul Continues

Executive Summary

As AstraZeneca’s global product chief Marc Dunoyer moves on to the CFO job, he leaves a newly restructured, active, and decentralized dealmaking organization.

You may also be interested in...

AstraZeneca Says Revamped Pipeline Will Return It To Health, But Pitfalls Remain

Equipped with 19 drug candidates for Phase III trials over the next two years, Britain’s AstraZeneca says it’s finally “on a roll.” But the troubled medicine maker still expects earnings to keep falling in 2014 amid uncertainty over heart drug Brilinta and likely generic competition to Nexium in the U.S.

AZ’s MedImmune Buys Spirogen To Boost Oncology ADC Capability

AstraZeneca agreed to pay $200 million upfront and $240 million in predefined milestones for Spirogen to enhance its early oncology pipeline with linked tumor-targeted antibody drug conjugates. The company simultaneously announced a collaboration with ADC Therapeutics to jointly develop ADCs.

MedImmune To Enhance Oncology Pipeline With Buyout Of Neighbor Amplimmune

Deal brings AstraZeneca’s biologics subsidiary an anti-PD1 monoclonal antibody that could enter clinical trials this autumn. MedImmune will pay $225 million for the privately held biotech, with milestones of up to $275 million possible down the line.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts